Cargando…

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

BACKGROUND: Combination CDK4/6 inhibitor and endocrine therapy has been shown to significantly improve progression‐free survival (PFS) in patients with hormone receptor (HR)‐positive, HER2‐negative metastatic breast cancer (mBC). The aim of this retrospective study was to evaluate the real‐world ben...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, James, Zhong, Xiaojun, Ma, Junjie, Sun, Weihong, Han, Hyo S., Soliman, Hatem H., Loftus, Loretta S., Costa, Ricardo L. B., Armaghani, Avan J., Soyano‐Muller, Aixa E., Czerniecki, Brian J., Lee, M. Catherine, Kiluk, John V., Khakpour, Nazanin, Hoover, Susan J., Laronga, Christine, Khong, Hung T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559460/ https://www.ncbi.nlm.nih.gov/pubmed/34590788 http://dx.doi.org/10.1002/cam4.4295

Ejemplares similares

A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes
por: Bari, Shahla, et al.
Publicado: (2022)

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study
por: Ahmed, Kamran A., et al.
Publicado: (2021)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Early treatment-related neutropenia predicts response to palbociclib
por: McAndrew, Nicholas P., et al.
Publicado: (2020)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Oncoplastic Surgery: Keeping It Simple With 5 Essential Volume Displacement Techniques for Breast Conservation in a Patient With Moderate- to Large-Sized Breasts
por: Chatterjee, Abhishek, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study
por: Barakat, Elie, et al.
Publicado: (2021)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Lee, Yeonhong, et al.
Publicado: (2023)

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2021)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
por: Armaghani, Avan J, et al.
Publicado: (2020)

Translating palbociclib to the clinic for DIPG - What is truly achievable?
por: Franshaw, Laura, et al.
Publicado: (2019)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Neuroendocrine Tumor Involving the Epicardium
por: Soyano, Aixa E., et al.
Publicado: (2017)

Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China
por: Wu, Xinyu, et al.
Publicado: (2023)

Efficacy and safety of palbociclib plus endocrine therapy for patients with HR(+)/HER2(−) advanced breast cancer in real-world clinical practice
por: Zhong, Bingqian, et al.
Publicado: (2022)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial
por: Alsaleh, K., et al.
Publicado: (2023)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy
por: Bui, Tam Binh V, et al.
Publicado: (2019)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4(+) Th1 Responses and Potential Use as a Cancer Vaccine
por: Basu, Amrita, et al.
Publicado: (2022)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Endocrine Regulation of Maturation and Sex Change in Groupers
por: Soyano, Kiyoshi, et al.
Publicado: (2022)

Authors' Reply to “Translating palbociclib to the clinic for DIPG - What is truly achievable?”
por: Sun, Yu, et al.
Publicado: (2019)

Dopamine Does Not Appear to Affect Mental Rotation in Parkinson’s Disease
por: Crucian, Gregory P., et al.
Publicado: (2014)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination
por: Zachariah, Nadia Nocera, et al.
Publicado: (2021)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_94d3ouefjlro8p72j8g319htkl